Study and Preparation of Multifunctional Poly(L-Lysine)@Hyaluronic Acid Nanopolyplexes for the Effective Delivery of Tumor Suppressive MiR-34a into Triple-Negative Breast Cancer Cells

Overview

Journal Materials (Basel)

Publisher MDPI

Date 2020 Dec 1

PMID 33255217

Citations 3

Authors

Jamila Djafari

Javier Fernandez-Lodeiro

Hugo M Santos

Julia Lorenzo

Sergi Rodriguez-Calado

Emilia Bertolo

Jose Luis Capelo-Martinez

Carlos Lodeiro

Affiliations

Soon will be listed here.

Abstract

Non-viral gene delivery using exogenous microRNAs is a potential strategy for fighting cancers with poor prognosis and which lack specific therapies, such as triple-negative breast cancer (TNBC). Herein we report the synthesis of six nontoxic electrostatic polymeric nanocapsules (P1 to P6) for microRNA delivery in TNBC cells. 1H Nuclear Magnetic Resonance (NMR) spectroscopy and Scanning Electron Microscopy (SEM) were used to characterize the nanopolyplexes, synthesized with Poly(L-Lysine) and hyaluronic acid (Ha). Studies on the activity of the ternary HA/PLI/miRNA-34 nanopolyplexes towards TNBC cell line MDA-MB-231 were conducted. The nanopolyplexes mediated intracellular restoration of tumor suppressor miR34a was evaluated by using Western blotting to quantify the expression level of the Bcl-2 protein. The results suggest that the P5, with a ratio PLI/Ha of 0.05, was the most promising for the delivery of miR-34a into TNBC cells; the P5 nanocapsules were able to reduce Bcl-2 expression at a protein level, and had an effect in the overall cell viability after 24 h treatment.

Citing Articles

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.

The Effect of Concentration, Temperature, and pH on the Formation of Hyaluronic Acid-Surfactant Nanohydrogels.

Seres L, Csapo E, Varga N, Juhasz A Gels. 2023; 9(7).

PMID: 37504408 PMC: 10379036. DOI: 10.3390/gels9070529.

Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.

Ahmed R, Samanta S, Banerjee J, Kar S, Dash S Curr Res Pharmacol Drug Discov. 2022; 3:100131.

PMID: 36568259 PMC: 9780070. DOI: 10.1016/j.crphar.2022.100131.

References

Bail S, Swerdel M, Liu H, Jiao X, Goff L, Hart R . Differential regulation of microRNA stability. RNA. 2010; 16(5):1032-9. PMC: 2856875. DOI: 10.1261/rna.1851510. View

Valcourt D, Day E . Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers. Mol Ther Nucleic Acids. 2020; 21:290-298. PMC: 7332498. DOI: 10.1016/j.omtn.2020.06.003. View

Kim E, Yang J, Kim H, An Y, Lim E, Lee G . Hyaluronic acid receptor-targetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. Biomaterials. 2013; 34(17):4327-38. DOI: 10.1016/j.biomaterials.2013.02.006. View

Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z . Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014; 35(14):4333-44. DOI: 10.1016/j.biomaterials.2014.02.006. View

Zhao T, Li J, Chen A . MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab. 2010; 299(1):E110-6. PMC: 2904051. DOI: 10.1152/ajpendo.00192.2010. View

Collina F, di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M . Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer. Biomed Res Int. 2015; 2015:158682. PMC: 4609334. DOI: 10.1155/2015/158682. View

Inao T, Iida Y, Moritani T, Okimoto T, Tanino R, Kotani H . Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Oncotarget. 2018; 9(39):25545-25556. PMC: 5986635. DOI: 10.18632/oncotarget.25370. View

Jang E, Kim E, Son H, Lim E, Lee H, Choi Y . Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy. Biomaterials. 2016; 105:12-24. DOI: 10.1016/j.biomaterials.2016.07.036. View

Xu M, McCanna D, Sivak J . Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells. J Pharmacol Toxicol Methods. 2014; 71:1-7. DOI: 10.1016/j.vascn.2014.11.003. View

10.

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H . Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008; 7(16):2591-600. DOI: 10.4161/cc.7.16.6533. View

11.

Kumari P, Ghosh B, Biswas S . Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2015; 24(3):179-91. DOI: 10.3109/1061186X.2015.1051049. View

12.

Chan L, Cox B . Kinetics of amide formation through carbodiimide/N-hydroxybenzotriazole (HOBt) couplings. J Org Chem. 2007; 72(23):8863-9. DOI: 10.1021/jo701558y. View

13.

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

14.

Zhao Q, Chen J, Lv T, He C, Tang G, Liang W . N/P ratio significantly influences the transfection efficiency and cytotoxicity of a polyethylenimine/chitosan/DNA complex. Biol Pharm Bull. 2009; 32(4):706-10. DOI: 10.1248/bpb.32.706. View

15.

Youle R, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2007; 9(1):47-59. DOI: 10.1038/nrm2308. View

16.

Misso G, Di Martino M, De Rosa G, Farooqi A, Lombardi A, Campani V . Mir-34: a new weapon against cancer?. Mol Ther Nucleic Acids. 2014; 3:e194. PMC: 4222652. DOI: 10.1038/mtna.2014.47. View

17.

Tros de Ilarduya C, Sun Y, Duzgunes N . Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci. 2010; 40(3):159-70. DOI: 10.1016/j.ejps.2010.03.019. View